{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:03:32Z","timestamp":1788959012587,"version":"build-2803163510"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Aim:<\/jats:bold> To characterize perceived benefits and challenges experienced by medicinal cannabis users.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> An anonymous online survey collected demographics, health information, and open-ended responses from medicinal cannabis users regarding perceptions, motivations, and experience of treatment. Qualitative open-ended responses were thematically analyzed.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Respondents (<jats:italic>N<\/jats:italic> = 808) were predominantly White (79%), female (63%), with a mean (SD) age of 38 (20). Two hundred eighty-four (35%) respondents provided data on a dependent family member (e.g., child; 22% of total sample). Most used cannabidiol (CBD)-dominant products (58%), primarily for neurological disorders (38%) or pain (25%). Primary motivations for medicinal cannabis use were based on beliefs that traditional treatments were ineffective and\/or had intolerable side effects (51%), positive scientific or media portrayals of the safety\/efficacy of cannabis as a therapeutic (29%), or preference for \u201cnatural\u201d treatments over pharmaceuticals (21%). A majority of respondents (77%) attributed positive effects to the medicinal use of cannabis\/cannabinoids. These included physical symptom improvements such as reduced pain (28%), improved sleep (18%), and seizure reduction (18%), and mental health improvements including reduced anxiety (22%) and improved mood (11%). Additionally, respondents reported reduced use of other medications (e.g., opioids) (12%), and improved quality of life (14%). Problems associated with use were cited by 41% of respondents, and included unwanted side effects (16%), lack of information or medical support (16%), prohibitive costs (12%), and legal concerns (10%).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Most participants reported benefits from cannabis use for a variety of conditions where traditional treatments were ineffective or unacceptable. Concerns regarding cannabis side effects, legality, lack of information, and cost were raised. Data indicate greater research and education on the safety and efficacy of medicinal cannabis\/cannabinoid use is warranted.<\/jats:p>","DOI":"10.3389\/fphar.2022.965535","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T04:32:30Z","timestamp":1662438750000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Online survey of medicinal cannabis users: Qualitative analysis of patient-level data"],"prefix":"10.3389","volume":"13","author":[{"given":"Albert","family":"Garcia-Romeu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Elmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhiannon E.","family":"Mayhugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas J.","family":"Schlienz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin L.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin C.","family":"Strickland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Bonn-Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Vandrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1080\/02791072.2019.1626953","article-title":"Use of cannabis to relieve pain and promote sleep by customers at an adult use dispensary","volume":"51","author":"Bachhuber","year":"2019","journal-title":"J. Psychoact. Drugs"},{"key":"B2","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.36076\/ppj.2008\/11\/s105","article-title":"Opioid complications and side effects","volume":"11","author":"Benyamin","year":"2008","journal-title":"Pain Physician"},{"key":"B3","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","article-title":"Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis","volume":"6","author":"Black","year":"2019","journal-title":"Lancet. Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/can.2019.0045","article-title":"Priority considerations for medicinal cannabis-related research","volume":"4","author":"Bonn-Miller","year":"2019","journal-title":"Cannabis Cannabinoid Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1089\/can.2020.0056","article-title":"The long-term, prospective, therapeutic impact of cannabis on post-traumatic stress disorder","volume":"7","author":"Bonn-Miller","year":"2022","journal-title":"Cannabis Cannabinoid Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual. Res. Psychol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/jama.2016.18900","article-title":"Use of marijuana for medical purposes among adults in the United States","volume":"317","author":"Compton","year":"2017","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1177\/1525822x08317166","article-title":"Using pooled kappa to summarize interrater agreement across many items","volume":"20","author":"De Vries","year":"2008","journal-title":"Field Methods"},{"key":"B9","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.lfs.2005.09.011","article-title":"Chemical constituents of marijuana: The complex mixture of natural cannabinoids","volume":"78","author":"ElSohly","year":"2005","journal-title":"Life Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4088\/pcc.v03n0105","article-title":"SSRI antidepressant medications: adverse effects and tolerability","volume":"3","author":"Ferguson","year":"2001","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1528-1167.2007.00992.x","article-title":"Refractory epilepsy: clinical overview","volume":"48","author":"French","year":"2007","journal-title":"Epilepsia"},{"key":"B12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4088\/JCP.8133su1c.02","article-title":"Identifying difficult-to-treat depression: differential diagnosis, subtypes, and comorbidities","volume":"70","author":"Gaynes","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/S0140-6736(19)31789-1","article-title":"Public health implications of legalising the production and sale of cannabis for medicinal and recreational use","volume":"394","author":"Hall","year":"2019","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/0091-3057(90)90028-g","article-title":"Acute and residual effects of marijuana: Profiles of plasma THC levels, physiological, subjective, and performance measures","volume":"37","author":"Heishman","year":"1990","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B16","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.yebeh.2015.04.009","article-title":"Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and lennox-gastaut syndrome","volume":"47","author":"Hussain","year":"2015","journal-title":"Epilepsy Behav."},{"key":"B17","doi-asserted-by":"publisher","first-page":"116717","DOI":"10.1016\/j.jns.2020.116717","article-title":"Clinical uses of cannabis and cannabinoids in the United States","volume":"411","author":"Levinsohn","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.addbeh.2016.05.015","article-title":"Comparing adults who use cannabis medically with those who use recreationally: Results from a national sample","volume":"61","author":"Lin","year":"2016","journal-title":"Addict. Behav."},{"key":"B19","doi-asserted-by":"publisher","first-page":"729800","DOI":"10.3389\/fpsyt.2021.729800","article-title":"Antidepressant and anxiolytic effects of medicinal cannabis use in an observational trial","volume":"12","author":"Martin","year":"2021","journal-title":"Front. Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","first-page":"276","DOI":"10.11613\/bm.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1185\/030079907X167525","article-title":"Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting","volume":"23","author":"Meiri","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"B22","volume-title":"The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research","year":"2017"},{"key":"B23","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","article-title":"Adverse effects of antiepileptic drugs","volume":"11","author":"Perucca","year":"2012","journal-title":"Lancet. Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s13643-019-1243-x","article-title":"Benefits and harms of medical cannabis: A scoping review of systematic reviews","volume":"8","author":"Pratt","year":"2019","journal-title":"Syst. Rev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1021\/np900067k","article-title":"Biologically active cannabinoids from high-potency Cannabis sativa","volume":"72","author":"Radwan","year":"2009","journal-title":"J. Nat. Prod."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1111\/j.1476-5381.2011.01238.x","article-title":"Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects","volume":"163","author":"Russo","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejim.2018.01.023","article-title":"Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer","volume":"49","author":"Schleider","year":"2018","journal-title":"Eur. J. Intern. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1089\/can.2019.0096","article-title":"A cross-sectional and prospective comparison of medicinal cannabis users and controls on self-reported health","volume":"6","author":"Schlienz","year":"2020","journal-title":"Cannabis Cannabinoid Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/j.1532-2149.2013.00445.x","article-title":"A double-blind, randomized, placebo-controlled, parallel group study of THC\/CBD spray in peripheral neuropathic pain treatment","volume":"18","author":"Serpell","year":"2014","journal-title":"Eur. J. Pain"},{"key":"B30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.copsyc.2019.04.002","article-title":"Changing landscape of cannabis: Novel products, formulations, and methods of administration","volume":"30","author":"Spindle","year":"2019","journal-title":"Curr. Opin. Psychol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1097\/j.pain.0000000000001293","article-title":"Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies","volume":"159","author":"Stockings","year":"2018","journal-title":"Pain"},{"key":"B32","doi-asserted-by":"publisher","first-page":"108205","DOI":"10.1016\/j.yebeh.2021.108205","article-title":"Cross-sectional and longitudinal evaluation of cannabidiol (CBD) product use and health among people with epilepsy","volume":"122","author":"Strickland","year":"2021","journal-title":"Epilepsy Behav."},{"key":"B33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/09540261.2018.1491107","article-title":"The cannabis conundrum: steering policy and medicine with insufficient data","volume":"30","author":"Vandrey","year":"2018","journal-title":"Int. Rev. Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e0193959","DOI":"10.1371\/journal.pone.0193959","article-title":"A hierarchical anatomical classification schema for prediction of phenotypic side effects","volume":"13","author":"Wadhwa","year":"2018","journal-title":"PloS One"},{"key":"B35","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jpain.2015.03.008","article-title":"Efficacy of inhaled cannabis on painful diabetic neuropathy","volume":"16","author":"Wallace","year":"2015","journal-title":"J. Pain"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"key":"B37","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2147\/JPR.S113138","article-title":"A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis","volume":"9","author":"Wilsey","year":"2016","journal-title":"J. Pain Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0140-6736(03)14738-1","article-title":"Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial","volume":"362","author":"Zajicek","year":"2003","journal-title":"Lancet"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.965535\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T04:32:38Z","timestamp":1662438758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.965535\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":37,"alternative-id":["10.3389\/fphar.2022.965535"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.965535","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"article-number":"965535"}}